FibroGen, Inc. is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:FGEN
- CUSIP: N/A
- Web: www.fibrogen.com
Capitalization:- Market Cap: $2.36 billion
- Outstanding Shares: 69,944,000
Average Prices:- 50 Day Moving Avg: $32.38
- 200 Day Moving Avg: $27.26
- 52 Week Range: $15.60 - $35.85
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -51.06
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $178.19 million
- Price / Sales: 13.23
- Book Value: $2.04 per share
- Price / Book: 16.52
Profitability:- EBIDTA: ($52,180,000.00)
- Net Margins: -37.60%
- Return on Equity: -36.41%
- Return on Assets: -14.13%
Debt:- Debt-to-Equity Ratio: 0.65%
- Current Ratio: 4.27%
- Quick Ratio: 4.27%
Misc:- Average Volume: 444,089 shs.
- Beta: 1.77
- Short Ratio: 4.76
Frequently Asked Questions for FibroGen (NASDAQ:FGEN)
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen, Inc (NASDAQ:FGEN) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.11. The company earned $26.89 million during the quarter, compared to analyst estimates of $26.02 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. View FibroGen's Earnings History.
Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?
8 brokers have issued 1-year target prices for FibroGen's stock. Their predictions range from $31.00 to $52.00. On average, they anticipate FibroGen's share price to reach $42.67 in the next twelve months. View Analyst Ratings for FibroGen.
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE), INC Research Holdings (INCR), Intrexon Corporation (XON), Ligand Pharmaceuticals Incorporated (LGND), Ironwood Pharmaceuticals (IRWD), Blueprint Medicines Corporation (BPMC), Emergent Biosolutions (EBS) and Foundation Medicine (FMI).
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder
- Pat Cotroneo, Chief Financial Officer, Vice President - Finance
- Frank H. Valone M.D., Senior Fellow, Clinical Development
- K. Peony Yu M.D., Chief Medical Officer
- Jeffrey L. Edwards, Independent Director
- Jeffrey William Henderson, Independent Director
- Thomas F. Kearns Jr., Independent Director
- Kalevi Kurkijarvi Ph.D., Independent Director
- Rory B. Riggs, Independent Director
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Who owns FibroGen stock?
FibroGen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include
ECOR1 CAPITAL, LLC
Total Shares:
1,322,991
(1.90%), Omega Fund Management LLC (0.90%), Handelsbanken Fonder AB (0.34%), Rothschild Asset Management Inc. (0.26%), Boston Advisors LLC (0.25%) and Strs Ohio (0.20%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Who sold FibroGen stock? Who is selling FibroGen stock?
FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, Acadian Asset Management LLC, Capital Impact Advisors LLC and Rothschild Asset Management Inc.. Company insiders that have sold FibroGen stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.
Who bought FibroGen stock? Who is buying FibroGen stock?
FibroGen's stock was acquired by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Handelsinvest Investeringsforvaltning, Russell Investments Group Ltd., Great West Life Assurance Co. Can and Strs Ohio. View Insider Buying and Selling for FibroGen.
How do I buy FibroGen stock?
Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FibroGen stock can currently be purchased for approximately $33.70.
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for FibroGen (NASDAQ:FGEN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.88) |
| Consensus Price Target: | $42.67 (26.61% upside) |
Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/21/2017 | Goldman Sachs Group, Inc. (The) | Downgrade | Buy -> Neutral | $31.00 | Medium |  |
| 7/10/2017 | Jefferies Group LLC | Initiated Coverage | Buy -> Buy | $50.00 | High | |
| 6/26/2017 | Citigroup Inc. | Reiterated Rating | Buy | $48.00 | High | |
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | Medium | |
| 6/22/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $32.00 -> $38.00 | Low | |
| 1/18/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | | N/A | |
| 11/9/2016 | Leerink Swann | Reiterated Rating | Buy | $52.00 | N/A | |
| 8/9/2016 | Credit Suisse Group | Reiterated Rating | Buy | $37.00 | N/A | |
| 9/23/2015 | Lake Street Capital | Initiated Coverage | Hold | $25.00 | N/A | |
(Data available from 7/28/2015 forward)
Earnings History for FibroGen (NASDAQ:FGEN)Earnings History by Quarter for FibroGen (NASDAQ FGEN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.63) | ($0.52) | $26.02 million | $26.89 million | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.53) | ($0.54) | $19.29 million | $31.91 million | View | Listen | |
| 11/8/2016 | Q3 | ($0.63) | ($0.38) | $24.30 million | $30.10 million | View | Listen | |
| 8/8/2016 | Q2 | $0.36 | $0.35 | $80.58 million | $89.28 million | View | Listen | |
| 5/9/2016 | Q116 | ($0.56) | ($0.45) | $16.89 million | $28.28 million | View | Listen | |
| 2/29/2016 | Q4 | ($0.54) | ($0.85) | $40.44 million | $24.44 million | View | Listen | |
| 11/12/2015 | Q3 | ($0.61) | ($0.74) | $28.74 million | $19.54 million | View | Listen | |
| 8/13/2015 | Q215 | $0.73 | $0.83 | $111.75 million | $120.55 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.53) | ($0.78) | $34.00 million | $16.30 million | View | N/A | |
| 3/26/2015 | Q414 | ($0.90) | ($0.82) | $16.49 million | $16.11 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for FibroGen (NASDAQ:FGEN)2017 EPS Consensus Estimate: ($1.96)
2018 EPS Consensus Estimate: ($1.70)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.77) | ($0.48) | ($0.63) |
| Q2 2017 | 3 | ($0.47) | ($0.43) | ($0.45) |
| Q3 2017 | 3 | ($0.46) | ($0.22) | ($0.37) |
| Q4 2017 | 3 | ($0.58) | ($0.45) | ($0.52) |
| Q1 2018 | 1 | ($0.87) | ($0.87) | ($0.87) |
| Q2 2018 | 1 | ($0.84) | ($0.84) | ($0.84) |
| Q3 2018 | 1 | $0.77 | $0.77 | $0.77 |
| Q4 2018 | 1 | ($0.76) | ($0.76) | ($0.76) |
(Data provided by Zacks Investment Research)
Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 43.87%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/25/2017 | Thomas B Neff | CEO | Sell | 38,636 | $35.09 | $1,355,737.24 | |
| 7/24/2017 | Thomas B Neff | CEO | Sell | 18,900 | $35.06 | $662,634.00 | |
| 7/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $33.45 | $66,900.00 | |
| 7/10/2017 | K Peony Yu | Insider | Sell | 5,000 | $32.98 | $164,900.00 | |
| 7/7/2017 | Thomas B Neff | CEO | Sell | 38,636 | $33.38 | $1,289,669.68 | |
| 7/6/2017 | Pat Cotroneo | VP | Sell | 4,000 | $34.00 | $136,000.00 | |
| 7/6/2017 | Thomas B Neff | CEO | Sell | 18,900 | $33.53 | $633,717.00 | |
| 6/22/2017 | Pat Cotroneo | VP | Sell | 3,000 | $32.00 | $96,000.00 | |
| 6/22/2017 | Thomas B Neff | CEO | Sell | 38,636 | $31.52 | $1,217,806.72 | |
| 6/19/2017 | Pat Cotroneo | VP | Sell | 5,500 | $30.00 | $165,000.00 | |
| 6/16/2017 | Thomas B Neff | CEO | Sell | 38,636 | $29.40 | $1,135,898.40 | |
| 6/15/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $28.50 | $57,000.00 | |
| 6/14/2017 | K Peony Yu | Insider | Sell | 3,721 | $28.95 | $107,722.95 | |
| 6/12/2017 | Pat Cotroneo | VP | Sell | 2,891 | $28.75 | $83,116.25 | |
| 6/12/2017 | Toshinari Tamura | Director | Sell | 30,000 | $28.89 | $866,700.00 | |
| 6/6/2017 | Thomas F Kearns Jr | Director | Sell | 18,000 | $28.71 | $516,780.00 | |
| 5/31/2017 | Thomas B Neff | CEO | Sell | 38,636 | $26.21 | $1,012,649.56 | |
| 5/16/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $27.40 | $54,800.00 | |
| 5/16/2017 | Thomas B Neff | CEO | Sell | 38,636 | $27.70 | $1,070,217.20 | |
| 5/15/2017 | Thomas B Neff | CEO | Sell | 18,900 | $27.75 | $524,475.00 | |
| 5/10/2017 | K Peony Yu | Insider | Sell | 5,000 | $26.38 | $131,900.00 | |
| 4/25/2017 | K Peony Yu | Insider | Sell | 5,000 | $28.00 | $140,000.00 | |
| 4/25/2017 | Pat Cotroneo | VP | Sell | 6,500 | $28.00 | $182,000.00 | |
| 4/25/2017 | Thomas B Neff | CEO | Sell | 38,636 | $26.92 | $1,040,081.12 | |
| 4/24/2017 | Thomas B Neff | CEO | Sell | 18,900 | $26.35 | $498,015.00 | |
| 4/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $25.25 | $50,500.00 | |
| 4/13/2017 | Thomas B Neff | CEO | Sell | 38,636 | $24.79 | $957,786.44 | |
| 4/4/2017 | Thomas B Neff | CEO | Sell | 38,636 | $23.92 | $924,173.12 | |
| 3/21/2017 | Thomas B Neff | CEO | Sell | 38,636 | $24.34 | $940,400.24 | |
| 3/20/2017 | Thomas B Neff | CEO | Sell | 18,900 | $24.88 | $470,232.00 | |
| 3/15/2017 | Thomas B Neff | CEO | Sell | 38,636 | $25.07 | $968,604.52 | |
| 2/16/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $24.45 | $48,900.00 | |
| 2/14/2017 | Thomas B Neff | CEO | Sell | 38,636 | $23.94 | $924,945.84 | |
| 2/13/2017 | Thomas B Neff | CEO | Sell | 18,900 | $23.97 | $453,033.00 | |
| 2/9/2017 | Thomas B Neff | CEO | Sell | 37,798 | $23.46 | $886,741.08 | |
| 1/27/2017 | Thomas B Neff | CEO | Sell | 37,798 | $23.29 | $880,315.42 | |
| 1/19/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $24.90 | $49,800.00 | |
| 1/12/2017 | Thomas B Neff | CEO | Sell | 37,798 | $23.85 | $901,482.30 | |
| 1/11/2017 | Pat Cotroneo | VP | Sell | 6,500 | $24.00 | $156,000.00 | |
| 1/10/2017 | K Peony Yu | Insider | Sell | 5,000 | $23.56 | $117,800.00 | |
| 12/28/2016 | Thomas B Neff | CEO | Sell | 37,798 | $20.74 | $783,930.52 | |
| 12/16/2016 | Rory B Riggs | Director | Sell | 20,000 | $20.87 | $417,400.00 | |
| 12/13/2016 | Thomas B Neff | CEO | Sell | 37,798 | $21.24 | $802,829.52 | |
| 12/12/2016 | Pat Cotroneo | VP | Sell | 2,344 | $22.05 | $51,685.20 | |
| 12/12/2016 | Thomas B Neff | CEO | Sell | 18,899 | $21.48 | $405,950.52 | |
| 11/29/2016 | Thomas B Neff | CEO | Sell | 37,798 | $22.80 | $861,794.40 | |
| 11/28/2016 | Thomas B Neff | CEO | Sell | 18,899 | $22.74 | $429,763.26 | |
| 11/18/2016 | Thomas F Kearns Jr | Director | Sell | 18,000 | $22.40 | $403,200.00 | |
| 11/17/2016 | Thomas B Neff | CEO | Sell | 37,798 | $22.29 | $842,517.42 | |
| 11/1/2016 | Thomas B Neff | CEO | Sell | 37,798 | $16.76 | $633,494.48 | |
| 10/19/2016 | Thomas B Neff | CEO | Sell | 37,798 | $17.75 | $670,914.50 | |
| 10/18/2016 | Thomas B Neff | CEO | Sell | 18,899 | $17.94 | $339,048.06 | |
| 10/4/2016 | Thomas B Neff | CEO | Sell | 18,899 | $20.67 | $390,642.33 | |
| 10/3/2016 | Thomas B Neff | CEO | Sell | 18,899 | $20.55 | $388,374.45 | |
| 9/21/2016 | Thomas B Neff | CEO | Sell | 37,798 | $21.66 | $818,704.68 | |
| 9/14/2016 | K Peony Yu | Insider | Sell | 2,345 | $18.66 | $43,757.70 | |
| 9/12/2016 | Pat Cotroneo | VP | Sell | 2,345 | $18.22 | $42,725.90 | |
| 9/9/2016 | Thomas B Neff | CEO | Sell | 37,798 | $18.99 | $717,784.02 | |
| 8/26/2016 | Thomas B Neff | CEO | Sell | 37,798 | $17.80 | $672,804.40 | |
| 7/27/2016 | Thomas B Neff | CEO | Sell | 37,798 | $18.38 | $694,727.24 | |
| 7/13/2016 | Thomas B Neff | CEO | Sell | 27,000 | $17.50 | $472,500.00 | |
| 6/29/2016 | Thomas B Neff | CEO | Sell | 27,000 | $16.02 | $432,540.00 | |
| 6/15/2016 | Pat Cotroneo | CFO | Sell | 1,796 | $16.49 | $29,616.04 | |
| 6/15/2016 | Thomas B Neff | CEO | Sell | 27,000 | $16.48 | $444,960.00 | |
| 6/10/2016 | K Peony Yu | Insider | Sell | 2,344 | $17.96 | $42,098.24 | |
| 6/3/2016 | Thomas B Neff | CEO | Sell | 27,000 | $18.99 | $512,730.00 | |
| 5/20/2016 | Thomas B Neff | CEO | Sell | 27,000 | $17.68 | $477,360.00 | |
| 5/16/2016 | Pat Cotroneo | CFO | Sell | 6,107 | $17.60 | $107,483.20 | |
| 5/3/2016 | Thomas B Neff | CEO | Sell | 27,000 | $17.78 | $480,060.00 | |
| 4/20/2016 | Thomas B Neff | CEO | Sell | 27,000 | $19.98 | $539,460.00 | |
| 4/19/2016 | Thomas B Neff | CEO | Sell | 13,500 | $20.21 | $272,835.00 | |
| 4/5/2016 | Thomas B Neff | CEO | Sell | 27,000 | $21.11 | $569,970.00 | |
| 4/1/2016 | Frank H Md Valone | Insider | Sell | 10,750 | $21.11 | $226,932.50 | |
| 3/22/2016 | Thomas B Neff | CEO | Sell | 27,000 | $18.74 | $505,980.00 | |
| 3/8/2016 | Thomas B Neff | CEO | Sell | 27,000 | $19.62 | $529,740.00 | |
| 3/1/2016 | Frank H Md Valone | Insider | Sell | 10,750 | $16.84 | $181,030.00 | |
| 2/23/2016 | Thomas B Neff | CEO | Sell | 27,000 | $19.11 | $515,970.00 | |
| 2/22/2016 | Thomas B Neff | CEO | Sell | 13,500 | $19.81 | $267,435.00 | |
| 2/16/2016 | Frank H. Md Valone | insider | Sell | 10,750 | $18.41 | $197,907.50 | |
| 2/10/2016 | Thomas B. Neff | CEO | Sell | 27,000 | $15.31 | $413,370.00 | |
| 1/29/2016 | Thomas B. Neff | CEO | Sell | 27,000 | $19.41 | $524,070.00 | |
| 1/21/2016 | Thomas F Kearns Jr | Director | Sell | 1,572 | $22.08 | $34,709.76 | |
| 1/14/2016 | Thomas B. Neff | CEO | Sell | 27,000 | $23.69 | $639,630.00 | |
| 12/24/2015 | Thomas F. Kearns, Jr. | Director | Sell | 7,800 | $30.88 | $240,864.00 | |
| 12/23/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $30.10 | $812,700.00 | |
| 12/11/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $29.59 | $798,930.00 | |
| 12/10/2015 | K Peony Yu | VP | Sell | 1,093 | $28.96 | $31,653.28 | |
| 12/8/2015 | Miguel Madero | Director | Sell | 40,386 | $30.49 | $1,231,369.14 | |
| 11/30/2015 | K Peony Yu | VP | Sell | 5,000 | $30.00 | $150,000.00 | |
| 11/25/2015 | Pat Cotroneo | CFO | Sell | 5,000 | $30.00 | $150,000.00 | |
| 11/24/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $28.98 | $391,230.00 | |
| 11/24/2015 | Thomas F. Kearns, Jr. | Director | Sell | 3,900 | $29.00 | $113,100.00 | |
| 11/23/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $27.99 | $377,865.00 | |
| 11/23/2015 | Thomas F. Kearns, Jr. | Director | Sell | 3,900 | $28.02 | $109,278.00 | |
| 11/17/2015 | K Peony Yu | VP | Sell | 5,000 | $28.00 | $140,000.00 | |
| 11/10/2015 | K Peony Yu | VP | Sell | 5,000 | $25.62 | $128,100.00 | |
| 11/9/2015 | K Peony Yu | VP | Sell | 2,500 | $25.00 | $62,500.00 | |
| 11/2/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $23.18 | $231,800.00 | |
| 10/30/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $24.06 | $649,620.00 | |
| 10/21/2015 | Thomas F. Kearns, Jr. | Director | Sell | 7,800 | $23.83 | $185,874.00 | |
| 10/19/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $23.00 | $230,000.00 | |
| 10/19/2015 | K Peony Yu | VP | Sell | 5,000 | $24.00 | $120,000.00 | |
| 10/16/2015 | K Peony Yu | VP | Sell | 5,000 | $21.46 | $107,300.00 | |
| 10/16/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $21.86 | $590,220.00 | |
| 10/2/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $21.59 | $582,930.00 | |
| 10/1/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $21.38 | $213,800.00 | |
| 9/18/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $29.10 | $785,700.00 | |
| 9/15/2015 | Pat Cotroneo | CFO | Sell | 1,093 | $27.95 | $30,549.35 | |
| 9/14/2015 | Rory B. Riggs | Director | Sell | 50,000 | $27.61 | $1,380,500.00 | |
| 9/11/2015 | Miguel Madero | Director | Sell | 20,600 | $27.66 | $569,796.00 | |
| 9/10/2015 | K Peony Yu | VP | Sell | 1,093 | $27.84 | $30,429.12 | |
| 9/10/2015 | Pat Cotroneo | CFO | Sell | 7,500 | $27.33 | $204,975.00 | |
| 9/4/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $22.88 | $308,880.00 | |
| 9/3/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $22.92 | $309,420.00 | |
| 9/1/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $23.58 | $235,800.00 | |
| 7/23/2015 | Thomas B Neff | CEO | Sell | 27,000 | $24.71 | $667,170.00 | |
| 7/20/2015 | Frank H Md Valone | Insider | Sell | 1,000 | $23.70 | $23,700.00 | |
| 7/20/2015 | Pat Cotroneo | CFO | Sell | 7,881 | $23.47 | $184,967.07 | |
| 7/9/2015 | Thomas B Neff | CEO | Sell | 27,000 | $22.11 | $596,970.00 | |
| 7/6/2015 | K Peony Yu | VP | Sell | 5,381 | $22.69 | $122,094.89 | |
| 6/25/2015 | Thomas B Neff | CEO | Sell | 27,000 | $23.57 | $636,390.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for FibroGen (NASDAQ:FGEN)
Latest Headlines for FibroGen (NASDAQ:FGEN)
| Source: |
|
| Date | Headline |
|---|
 | FibroGen, Inc (NASDAQ:FGEN) CEO Sells $662,634.00 in Stock
www.americanbankingnews.com - July 26 at 7:58 PM |
| Thomas B. Neff Sells 38,636 Shares of FibroGen, Inc (NASDAQ:FGEN) Stock
www.americanbankingnews.com - July 26 at 7:17 PM |
| Goldman Sachs Group, Inc. (The) Lowers FibroGen, Inc (NASDAQ:FGEN) to Neutral
www.americanbankingnews.com - July 22 at 7:34 PM |
 | Congress Could Have Major Impact on Biotech Companies - PR Newswire (press release)
www.prnewswire.com - July 21 at 10:03 PM |
 | Teligent Shares Rise on FDA Approval for Erythromycin Topical Gel ... - TheStreet.com
www.thestreet.com - July 21 at 10:03 PM |
| FibroGen, Inc (NASDAQ:FGEN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 21 at 11:43 AM |
| Biotech Movers: Vertex Continues to Move on Data for CF Regimen - TheStreet.com
www.thestreet.com - July 20 at 4:17 PM |
| $34.80 Million in Sales Expected for FibroGen, Inc (FGEN) This Quarter
www.americanbankingnews.com - July 19 at 4:54 PM |
| Contrasting Adamas Pharmaceuticals (ADMS) and FibroGen (NASDAQ:FGEN)
www.americanbankingnews.com - July 19 at 8:51 AM |
| FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares
www.americanbankingnews.com - July 18 at 7:52 PM |
| Zacks: Brokerages Expect FibroGen, Inc (NASDAQ:FGEN) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - July 17 at 10:49 AM |
| Brokers Issue Forecasts for FibroGen, Inc's Q2 2017 Earnings (NASDAQ:FGEN)
www.americanbankingnews.com - July 13 at 10:50 AM |
| FibroGen, Inc (FGEN) Insider Sells $164,900.00 in Stock
www.americanbankingnews.com - July 11 at 10:52 PM |
| FibroGen, Inc (FGEN) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - July 10 at 5:26 PM |
| FibroGen, Inc (FGEN) VP Sells $136,000.00 in Stock
www.americanbankingnews.com - July 7 at 8:41 PM |
| FibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 Shares
www.americanbankingnews.com - July 7 at 8:16 PM |
| FibroGen, Inc (FGEN) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts
www.americanbankingnews.com - June 28 at 7:32 AM |
| FibroGen, Inc (FGEN) Given Buy Rating at Citigroup Inc.
www.americanbankingnews.com - June 26 at 5:50 PM |
| FibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 26 at 10:53 AM |
| FibroGen, Inc (FGEN) Rating Reiterated by William Blair
www.americanbankingnews.com - June 26 at 8:16 AM |
| FibroGen, Inc (FGEN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 7:20 PM |
| FibroGen, Inc (FGEN) VP Pat Cotroneo Sells 3,000 Shares
www.americanbankingnews.com - June 23 at 7:32 PM |
| Insider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of Stock
www.americanbankingnews.com - June 23 at 7:15 PM |
| Analysts Expect FibroGen, Inc (FGEN) Will Announce Quarterly Sales of $34.74 Million
www.americanbankingnews.com - June 23 at 6:58 PM |
| Stifel Nicolaus Reiterates Buy Rating for FibroGen, Inc (FGEN)
www.americanbankingnews.com - June 22 at 8:34 PM |
 | FibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer - Nasdaq
www.nasdaq.com - June 22 at 9:46 AM |
 | FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
finance.yahoo.com - June 22 at 9:46 AM |
| FibroGen, Inc (FGEN) VP Sells $165,000.00 in Stock
www.americanbankingnews.com - June 21 at 8:05 PM |
| Analysts Expect FibroGen, Inc (FGEN) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - June 21 at 7:46 AM |
| Insider Selling: FibroGen, Inc (FGEN) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - June 19 at 7:57 PM |
| FibroGen, Inc (FGEN) Insider K Peony Yu Sells 3,721 Shares
www.americanbankingnews.com - June 16 at 7:58 PM |
| Pat Cotroneo Sells 2,891 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - June 14 at 8:19 PM |
| Toshinari Tamura Sells 30,000 Shares of FibroGen, Inc (FGEN) Stock
www.americanbankingnews.com - June 14 at 7:44 AM |
 | About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
feeds.benzinga.com - June 13 at 7:23 AM |
| Insider Selling: FibroGen Inc (FGEN) Director Sells 18,000 Shares of Stock
www.americanbankingnews.com - June 8 at 10:30 PM |
 | FibroGen (FGEN) Announces European Patent Office Decision to Maintain Patent Relating to Hypoxia-Inducible Factor ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:15 AM |
| European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
finance.yahoo.com - June 5 at 11:14 AM |
| FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017
finance.yahoo.com - June 2 at 6:31 PM |
| ETFs with exposure to FibroGen, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 6:31 PM |
| Insider Selling: FibroGen Inc (FGEN) CEO Sells 38,636 Shares of Stock
www.americanbankingnews.com - June 1 at 10:34 PM |
| $34.74 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter
www.americanbankingnews.com - May 27 at 7:33 AM |
| Zacks: Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - May 26 at 12:30 AM |
| ETFs with exposure to FibroGen, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:50 PM |
| FibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 4:56 PM |
| FibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares
www.americanbankingnews.com - May 17 at 11:15 PM |
| Insider Selling: FibroGen Inc (FGEN) CEO Sells 18,900 Shares of Stock
www.americanbankingnews.com - May 17 at 10:51 PM |
| FibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares
www.americanbankingnews.com - May 17 at 10:28 PM |
| Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact
finance.yahoo.com - May 15 at 4:50 PM |
| Insider Selling: FibroGen Inc (FGEN) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - May 12 at 8:01 PM |
| Equities Analysts Offer Predictions for FibroGen Inc's FY2017 Earnings (FGEN)
www.americanbankingnews.com - May 12 at 12:54 PM |
FibroGen (FGEN) Chart for Friday, July, 28, 2017
